ASPG and acute lymphoblastic leukemia: The phase I trial demonstrated that the combination of bortezomib (1.3 mg/m2) with a standard 4-drug chemotherapy reinduction backbone (vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin) (VPLD) was active with acceptable toxicity in pediatric patients with relapsed/refractory ALL.